Overview

The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Evaluate the effectiveness of the of kallikrein in the different drug frequency for acute anterior circulation cerebral infarction.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Huisheng Chen
Treatments:
Kallikreins
Criteria
Inclusion Criteria:

1. Age 18 to 80 years old;

2. First time diagnosed or have history of acute anterior circulation cerebral infarction
without serious sequelae (mRS = 0-2);

3. Acute anterior circulation cerebral infarction with large artery atherosclerotic
etiology;

4. Ability to randomize within 48 h of time last known free of new ischemic symptoms.

5. National Institute of Health stroke scale(NIHSS) ranges from 7 to 22;

6. signed written informed consent.

Exclusion Criteria:

1. Cerebral CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid
hemorrhage, etc.;

2. Transient ischemic attack;

3. Serious disturbance of consciousness: Glasgow Coma ScaleGCS(GCS)≤8;

4. Combined angiotensin-converting enzyme inhibitor(ACEI) less than 5 half-time
(according to its instruction), or need to be treated with ACEI;

5. Past or present suffering from hemorrhagic tendency of the disease;

6. The investigator in consideration of the other condition that the patients doesn't fit
to participate in this clinical study.